ESR1 and breast cancer: While the mean area for cytokeratin+ ER+ breast cancer tumors in bone tended to be smaller for lower E2 doses, the range of tumor sizes was similar across doses without a statistical difference in mean values [Figure 4A]; nor was there a significant linear trend for increasing doses.